Charles Schwab Investment Management Inc. Has $16.10 Million Stake in Novartis AG (NYSE:NVS)

Charles Schwab Investment Management Inc. boosted its stake in shares of Novartis AG (NYSE:NVS - Free Report) by 5.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 165,442 shares of the company's stock after purchasing an additional 8,186 shares during the period. Charles Schwab Investment Management Inc.'s holdings in Novartis were worth $16,099,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the stock. Fisher Asset Management LLC increased its holdings in Novartis by 17.4% during the fourth quarter. Fisher Asset Management LLC now owns 2,002,959 shares of the company's stock worth $194,908,000 after buying an additional 296,950 shares during the last quarter. FMR LLC lifted its stake in Novartis by 5.5% in the third quarter. FMR LLC now owns 1,353,412 shares of the company's stock valued at $155,669,000 after acquiring an additional 70,314 shares during the last quarter. Chevy Chase Trust Holdings LLC grew its position in shares of Novartis by 4.7% in the 4th quarter. Chevy Chase Trust Holdings LLC now owns 1,161,139 shares of the company's stock valued at $112,990,000 after acquiring an additional 52,044 shares during the period. Bank of Montreal Can increased its stake in shares of Novartis by 18.7% during the 3rd quarter. Bank of Montreal Can now owns 780,980 shares of the company's stock worth $90,289,000 after purchasing an additional 123,077 shares during the last quarter. Finally, Truist Financial Corp raised its holdings in shares of Novartis by 3.6% in the 4th quarter. Truist Financial Corp now owns 771,655 shares of the company's stock valued at $75,090,000 after purchasing an additional 27,092 shares during the period. 13.12% of the stock is currently owned by institutional investors.

Remove Ads

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Morgan Stanley initiated coverage on Novartis in a report on Wednesday, February 12th. They set an "underweight" rating for the company. UBS Group reiterated a "neutral" rating on shares of Novartis in a research note on Thursday, February 13th. Barclays reaffirmed an "underweight" rating on shares of Novartis in a report on Monday, February 3rd. StockNews.com upgraded shares of Novartis from a "buy" rating to a "strong-buy" rating in a report on Saturday, February 8th. Finally, HSBC cut shares of Novartis from a "hold" rating to a "reduce" rating in a research note on Wednesday, December 4th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $123.38.

Novartis Stock Performance

Shares of Novartis stock traded down $0.99 during trading on Monday, reaching $111.14. The company's stock had a trading volume of 1,492,637 shares, compared to its average volume of 1,474,466. The company has a quick ratio of 0.84, a current ratio of 1.04 and a debt-to-equity ratio of 0.48. The business's 50-day moving average price is $106.67 and its 200-day moving average price is $107.32. Novartis AG has a 52 week low of $92.35 and a 52 week high of $120.92. The firm has a market cap of $227.18 billion, a PE ratio of 18.90, a P/E/G ratio of 1.70 and a beta of 0.53.

Novartis (NYSE:NVS - Get Free Report) last posted its quarterly earnings data on Friday, January 31st. The company reported $1.98 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.80 by $0.18. Novartis had a net margin of 23.56% and a return on equity of 37.24%. Equities analysts forecast that Novartis AG will post 8.45 earnings per share for the current year.

Novartis Announces Dividend

The business also recently disclosed a dividend, which was paid on Wednesday, March 12th. Shareholders of record on Wednesday, March 12th were paid a dividend of $3.8695 per share. The ex-dividend date was Wednesday, March 12th. Novartis's dividend payout ratio (DPR) is presently 42.69%.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.